And another one bites the dust. Emerald Health Therapeutics (CSE: EMH), one of the first players to enter the Canadian cannabis sector, this morning announced that it is getting out of both recreational and medical cannabis in Canada entirely.
The announcement comes just weeks after the firm revealed it has partnered with HYTN Cannabis to launch cannabis beverages in the country. Instead, the company has begun the process of soliciting purchasers for its Canadian cannabis assets, the proceeds of which will be used to strengthen the firms capital position.
The move is being made as the firm looks to cut back its monthly net cash burn. Instead, the firm will be pivoting to pharmaceutical development due to the expertise and experience in the field among its board members.
In making the announcement, Chairman Jim Heppell commented, “in a market with a very large number of cannabis operating licenses, increasing competition and declining retail prices, the path to achieving profitability and increasing shareholder value has been very challenging.”
The firms CEO, Riaz Bandali, will also be stepping down from his role with the company effective December 31.
Emerald Health last traded at $0.08 on the CSE.
Information for this briefing was found via Sedar and Emerald Health Therapeutics. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.